Massive study checks if pneumonia vaccine shields HIV patients
NCT ID NCT05794191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how effective the Prevnar 13 (PCV13) vaccine is at preventing pneumonia and related infections in adults with HIV. Researchers analyzed health records of over 350,000 people with HIV to compare those who got the vaccine with those who did not. The goal was to see if the vaccine reduces the risk of pneumococcal pneumonia and invasive disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prevnar 13 (PCV13) vaccine
What this could lead to
If the vaccine works well, it could help protect people with HIV from serious pneumonia and bloodstream infections caused by pneumococcus bacteria.
What could go wrong
This study used health records, not a controlled experiment, so results may be less reliable. The vaccine may not work as well in real-world settings or for all types of pneumonia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States